Regeneron will turn an abandoned Dell plant into a production facility and hire 300

Tarrytown, NY-based Regeneron ($REGN), maker of the hot-selling vision treatment Eylea, says it will hire 300 people for a new plant in Limerick, Ireland, once it finishes refurbishing the abandoned Dell computer facility there. The drugmaker said today that it will spend $300 million to turn the plant into a drug manufacturing facility and analytical lab, its first plant outside the U.S. Work starts next year and is to be completed by the end of 2016. Eylea has been churning out impressive results since the FDA approved it two years ago. It generated more than $1 billion in sales in the first 9 months of this year, nearly 30% of that outside the U.S., where Bayer Healthcare markets it. Story | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.